ElizabetaCPopaMD

Gastrointestinal Cancer, Head & Neck Cancer, Hematologic Oncology, Sarcoma

Associate Professor of Clinical Medicine, Weill Cornell Medical College

Overview of Dr. Popa

Dr. Elizabeta Popa is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from New York Medical College and has been in practice 18 years. Dr. Popa accepts several types of health insurance, listed below. She is one of 375 doctors at New York-Presbyterian Hospital and one of 118 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 10 publications and over 500 citings.

Office
1305 York Avenue
12th Floor
New York, NY 10021
Book by Phone+1(240) 478-6738

Education & Training

NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2004 - 2005
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2004
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 1999 - 2002
New York Medical CollegeClass of 1999

Certifications & Licensure

NY State Medical License 2000 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors Start of enrollment: 2009 Jul 01
Completed
Phase 1
A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30
Completed
Phase 2
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer Start of enrollment: 2011 Jun 01
Completed
Phase 1
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas Start of enrollment: 2017 Jul 25
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Spectrum of Findings Seen in Patients WithCholangiocarcinoma.
Andrea Siobhan Kierans, Areeb Lutfi, Maaz Khan Afghan, Sahrish Khan, Sana Javaid
International Journal of Surgical Pathology. 2024-09-24
12 citations
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.
Pashtoon Murtaza Kasi, Manuel Hidalgo, Mehraneh D Jafari, Heather Yeo, Lea Lowenfeld
Oncogene. 2023-10-01
6 citations
A pilot study treatment of malignant tumors using low-dose 18 F-fluorodeoxyglucose ( 18 F-FDG)
Doru Paul, Cristina M Ghiuzeli, Josephine Rini, Christopher J. Palestro, Edward K Fung
American Journal of Nuclear Medicine and Molecular Imaging. 2020-12-15

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS North Carolina BlueOptions PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment